CHMA News and Press, Chiasma Inc. From 03/22/21

Announcing new positive clinical data from its MPOWERED™ Phase 3 trial, Chiasma (CHMA) says MYCAPSSA has improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.In the maint...

Support.com (SPRT) +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU) +17% as Canadian Pacific to buy the company fo...

--Data supports MYCAPSSA ® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching fro...

Gainers: [[RUBY]] +16.8%. [[SALM]] +7.5%. [[NXPI]] +5%. [[CHMA]] +3.5%. [[UBX]] +2.7%.Losers: [[CLPS]] -4.2%. [[AMTX]] -3.9%. [[VRAY]] -3.2%. [[TPIC]] -2.8%. [[EOLS]] -2.5%. For further details see: NXPI, TPIC, EOLS and UBX among after-hours movers

-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platfo...

Image source: The Motley Fool. Chiasma (NASDAQ: CHMA) Q4 2020 Earnings Call Mar 04, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Chiasma (CHMA) Q4 2020 Earnings Call Transcript

Chiasma, Inc. (CHMA) Q4 2020 Results Conference Call March 04, 2021 05:00 PM ET Company Participants Glenn Garmont - Investor Relations Raj Kannan - Chief Executive Officer Anand Varadan - Executive Vice President and Chief Commercial Officer Bill Ludlam - Senior Vice President of Clinical De...

Chiasma (CHMA): Q4 GAAP EPS of -$0.32 beats by $0.03.Revenue of $0.96M misses by $0.14M.Press Release For further details see: Chiasma EPS beats by $0.03, misses on revenue

Phased launch of MYCAPSSA ® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEW...

NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9 th ...